C Ray Therapeutics Expands Role in Radiopharmaceutical Development and Supply

According to a recent LinkedIn post from C Ray Therapeutics, the company is positioning itself within a rapidly evolving radiopharmaceutical landscape highlighted at AACR 2026. The post points to growing momentum for alpha emitters such as ²²⁵Ac and ²¹²Pb, noting their increasing presence relative to ¹⁷⁷Lu despite ongoing supply and handling constraints.

The post also suggests that target diversity in radiopharmaceutical R&D is expanding beyond PSMA and SSTR2, with multiple antigens including DLL3, c-Met, FAP-α, TROP2 and HER2 showing preclinical or early clinical data. In addition, a widening mix of ligands and scaffolds, from antibodies and small molecules to nanobodies, DARPins and TCR-based constructs, indicates a broadening technology base that could open new therapeutic niches.

As shared in the post, early clinical data are beginning to emerge across several programs, with examples such as ¹⁷⁷Lu-DGUL in metastatic castration-resistant prostate cancer and HER2-targeted nanobody radiopharmaceuticals progressing into Phase 0/1. This pattern may signal an inflection toward clinical validation and could increase investor attention to platforms and service providers capable of supporting later-stage development.

Within this context, the post highlights C Ray Therapeutics’ role as an enabling partner on multiple programs, including ²²⁵Ac-RAX104 and ⁶⁴Cu-RAX301 for RadAlliance Therapeutics, where it reportedly supplied clinical materials and CRO services. The mention of an in-house ⁶⁴Cu production platform with multi-curie batch capacity suggests potential vertical integration from isotope production through clinical batch release, which could improve margins and operational control if demand scales.

The company’s work on ¹⁷⁷Lu-PSMA-3D1015 with 3D Medicines and Jiangnan University Hospital, where it handled process development and technology transfer to a hospital-based site, indicates a service-oriented model that may generate diversified revenue across geographies and partners. For investors, this combination of manufacturing infrastructure, clinical supply capabilities and exposure to a broad set of emerging radiopharmaceutical targets could position C Ray Therapeutics to benefit from increased capital flows into radiotheranostics and nuclear medicine.

The post also notes the company’s planned presence at SNMMI 2026 in Los Angeles, which may provide additional business development opportunities with sponsors seeking isotope supply and clinical manufacturing support. While specific financial metrics are not disclosed, the described activities imply expanding client relationships and participation in a growing segment of oncology drug development, factors that could be relevant to assessments of future deal flow and capacity utilization.